depression disorders are associated with serious dysfunction and depressive symptoms. cognitive slowing is a clear symptom observed in all depressed people. pvsat is a measure of cognitive function that specifically assesses visual information processing speed and flexibility, as well as calculation ability. the aim of the present study was to determine whether the paced visual serial addition ...

This study compared 19 older adults and 20 younger adults on the Groton Maze Learning Test((c)) (GMLT), a novel computerized hidden maze learning test that assesses processing speed, spatial learning efficiency, and error monitoring. Convergent validity of this test was assessed by comparing GMLT scores to Paced Auditory Serial Addition Test (PASAT) and Tower of Toronto (TOT) scores. In the ful...

PURPOSE To investigate the effects of divided attention on conventional automated perimetry (CAP) and luminance size threshold perimetry (LSTP). METHODS Ten healthy subjects, ages 27 to 65, with two perimetry types (CAP and LSTP) were tested in random order. At a later session, these tests were given with a mental workload to simulate the effect of anxiety or distraction on subjects performin...

While emotion dysregulation has been investigated as a key variable in the development and persistence of personality psychopathology, few studies have explored state emotion dysregulation among individuals with personality disorders (PDs). The current study addresses this void in the literature through a laboratory investigation of state emotion dysregulation among participants with and withou...

Impaired information processing speed (IPS) is common in multiple sclerosis (MS). As a measure of IPS the Paced Auditory Serial Addition Test (PASAT), the measure recommended for serial assessments by the National MS Society Task Force, is influenced by practice effects. Within session practice effects for the PASAT were examined in a sample of 30 individuals with MS. Significant practice effec...

Ten healthy volunteers (six males; four females) completed this double-blind, crossover design study of vigabatrin vs placebo. Subjects were tested on four occasions; at the baselines of the placebo and the vigabatrin phase, and two weeks thereafter. At time of testing, the dose of vigabatrin was 2 g daily. Changes in cognition were assessed using the Sternberg, the PASAT, the Stroop, and Criti...